` MANKIND (Mankind Pharma Ltd) vs BSE Sensex 30 Comparison - Alpha Spread

MANKIND
vs
BSE Sensex 30

Over the past 12 months, MANKIND has underperformed BSE Sensex 30, delivering a return of 2% compared to the BSE Sensex 30's 6% growth.

Stocks Performance
MANKIND vs BSE Sensex 30

Loading

Performance Gap
MANKIND vs BSE Sensex 30

Loading
MANKIND
BSE Sensex 30
Difference

Performance By Year
MANKIND vs BSE Sensex 30

Loading
MANKIND
BSE Sensex 30
Add Stock

Competitors Performance
Mankind Pharma Ltd vs Peers

BSE Sensex 30
MANKIND
LLY
JNJ
NOVO B
ROG
Add Stock

Mankind Pharma Ltd
Glance View

Market Cap
957.8B INR
Industry
Pharmaceuticals

Mankind Pharma Ltd. has carved a unique niche in the pharmaceutical landscape of India, emerging as a formidable entity through an intriguing blend of affordability and accessibility. Founded in 1995 by R. C. Juneja, the company has steadily grown its portfolio to encompass a vast range of pharmaceutical products spanning prescription medications, over-the-counter (OTC) drugs, and consumer healthcare goods. Operating with a distinctive business model rooted in the ethos of delivering quality medicine at affordable prices, Mankind Pharma reaches deep into the densely populated tier II and tier III cities of India, ensuring that healthcare is accessible to the masses who need it the most. This strategic outreach, coupled with strong marketing and distribution networks, serves as a cornerstone of its business success. The company’s financial health is buoyed by its diversified product range, which caters to multiple therapeutic areas including antibiotics, cardiovascular, antifungal, and gastrointestinal, among others. Their robust R&D initiatives further reinforce their competitive edge, enabling them to continually introduce new and effective products that resonate with both healthcare providers and consumers. Revenue streams are not just confined to domestic borders; Mankind Pharma has been expanding its footprint internationally, penetrating markets across Asia, Africa, and the Americas. By striking a strategic balance between volume-driven pricing models and extensive market reach, Mankind Pharma not only emphasizes profitability but also solidifies its commitment to public health initiatives globally, thus creating a sustainable and progressive business trajectory.

MANKIND Intrinsic Value
1 706.2131 INR
Overvaluation 29%
Intrinsic Value
Price
M
Back to Top